Iron overload in myelodysplastic syndromes

References

• Cazzola M, Malcovati L. Myelodysplastic syndromes – coping with ineffective hematopoiesis. N. Engl. J. Med.352(6), 536–538 (2005).
   PubMed Web of Science ®Google Scholar
• A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br. J. Haematol.103(4), 1070–1074 (1998).
   PubMed Web of Science ®Google Scholar
• Porter JB. Practical management of iron overload. Br. J. Haematol.115(2), 239–252 (2001).
   PubMed Web of Science ®Google Scholar
• Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic syndromes. Leuk. Lymphoma49(3), 427–438 (2008).
   PubMed Web of Science ®Google Scholar
• Mittelman M, Lugassy G, Merkel D et al. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines. Isr. Med. Assoc. J.10(5), 374–376 (2008).
   PubMed Web of Science ®Google Scholar
• Valent P, Krieger O, Stauder R et al. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur. J. Clin. Invest.38(3), 143–149 (2008).
   PubMed Web of Science ®Google Scholar
• Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J. Natl Compr. Canc. Netw.4(1), 91–96 (2006).
   PubMedGoogle Scholar
• Rose C, Cambier N, Mahieu M, Ernst O, Fenaux P. [Iron overload and myelodysplastic syndromes]. Transfus. Clin. Biol.8(5), 422–432 (2001).
   PubMed Web of Science ®Google Scholar
• Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am. J. Hematol.83(11), 858–861 (2008).
   PubMed Web of Science ®Google Scholar
• Alessandrino EP, Amadori S, Barosi G et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica87(12), 1286–1306 (2002).
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer112(5), 1089–1095 (2008).
   PubMed Web of Science ®Google Scholar
• Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int. J. Hematol.88(1), 24–29 (2008).
   PubMed Web of Science ®Google Scholar
• Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol.120(2), 187–200 (2003).
   PubMed Web of Science ®Google Scholar
• Wells RA, Leber B, Buckstein R et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk. Res.32(9), 1338–1353 (2008).
   PubMed Web of Science ®Google Scholar
• Weintraub LR, Conrad ME, Crosby WH. Regulation of the intestinal absorption of iron by the rate of erythropoiesis. Br. J. Haematol.11, 432–438 (1965).
   PubMedGoogle Scholar
• Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science306(5704), 2090–2093 (2004).
   PubMed Web of Science ®Google Scholar
• Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu. Rev. Nutr.26, 323–342 (2006).
   PubMed Web of Science ®Google Scholar
• Papanikolaou G, Tzilianos M, Christakis JI et al. Hepcidin in iron overload disorders. Blood105(10), 4103–4105 (2005).
   PubMed Web of Science ®Google Scholar
• Winder A, Lefkowitz R, Ghoti H et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br. J. Haematol.142(4), 669–671 (2008).
   PubMed Web of Science ®Google Scholar
• Ramirez JM, Schaad O, Durual S et al. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br. J. Haematol.144(2), 251–262 (2009).
   PubMed Web of Science ®Google Scholar
• Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med.13(9), 1096–1101 (2007).
   PubMed Web of Science ®Google Scholar
• Tamary H, Shalev H, Perez-Avraham G et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood112(13), 5241–5244 (2008).
   PubMed Web of Science ®Google Scholar
• Finkenstedt A, Bianchi P, Theurl I et al. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br. J. Haematol.144(5), 789–793 (2009).
   PubMed Web of Science ®Google Scholar
• Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci.23(3), 185–192 (2000).
   PubMedGoogle Scholar
• Breuer W, Ronson A, Slotki IN et al. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood95(9), 2975–2982 (2000).
   PubMed Web of Science ®Google Scholar
• Esposito BP, Breuer W, Sirankapracha P et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood102(7), 2670–2677 (2003).
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Cattaneo C, Cristiani S et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol. J.1(3), 153–158 (2000).
   PubMedGoogle Scholar
• Breuer W, Ermers MJ, Pootrakul P et al. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood97(3), 792–798 (2001).
   PubMed Web of Science ®Google Scholar
• Wang WC, Ahmed N, Hanna M. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias. J. Pediatr.108(4), 552–557 (1986).
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Breuer W, Sametband M et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator. Blood104(5), 1504–1510 (2004).
   PubMed Web of Science ®Google Scholar
• Jaeger M, Aul C, Sohngen D, Germing U, Schneider W. [Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes]. Beitr. Infusionsther.30, 464–468 (1992).
   PubMedGoogle Scholar
• Cazzola M, Barosi G, Gobbi PG et al. Natural history of idiopathic refractory sideroblastic anemia. Blood71(2), 305–312 (1988).
   PubMed Web of Science ®Google Scholar
• Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr. Med. Res. Opin.25(1), 139–147 (2009).
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Mody-Patel N, Chen ER. Clinical and economic consequences of myelodysplastic syndromes in the United States: an analysis of the medicare database. Blood112(11), A237 (2008) (Abstract 636).
   Google Scholar
• Malcovati L, Porta MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol.23(30), 7594–7603 (2005).
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Shan J, Faderl S et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia22(3), 538–543 (2008).
   PubMed Web of Science ®Google Scholar
• Takatoku M, Uchiyama T, Okamoto S et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur. J. Haematol.78(6), 487–494 (2007).
   PubMed Web of Science ®Google Scholar
• Sanz G, Nomdedeu B, Such E et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood112(11), 238a–239a (2008) (Abstarct 640).
   Google Scholar
• Chan LSA, Buckstein R, Reis MD et al. Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML? Blood112(11), A928 (2008) (Abstract 2685).
   PubMedGoogle Scholar
• Kersten MJ, Lange R, Smeets ME et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann. Hematol.73(5), 247–252 (1996).
   PubMed Web of Science ®Google Scholar
• Gattermann N, Schmid M, Della Porta M et al. Efficacy and safety of deferasirox (Exjade) during 1 year of treatment in transfusion-dependent patients with myelodsysplastic syndromes: results from EPIC Trial. Blood112(11), A235–A236 (2008) (Abstract 633).
   Google Scholar
• Jensen PD, Jensen FT, Christensen T et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood101(11), 4632–4639 (2003).
   PubMed Web of Science ®Google Scholar
• Porter J, Galanello R, Saglio G et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur. J. Haematol.80(2), 168–176 (2008).
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood107(9), 3455–3462 (2006).
   PubMed Web of Science ®Google Scholar
• List AF, Baer MR, Steensma DP, Raza A. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndrome (MDS). Blood112(11), A236 (2008) (Abstract 634).
   Google Scholar
• Rachmilewitz E, Merkel D, Ghoti H et al. Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox. Blood112(11), A924–A925 (2008) (Abstract 2675).
   PubMedGoogle Scholar
• Leitch HA, Leger CS, Goodman TA et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin. Leuk.2, 205–211 (2008).
   Google Scholar
• Rose C, Brechignac S, Vassilief D et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood110(11), A80–A81 (2007) (Abstract 249).
   Web of Science ®Google Scholar